SG Americas Securities LLC Acquires 8,581 Shares of Alector, Inc. (NASDAQ:ALEC)

SG Americas Securities LLC raised its stake in shares of Alector, Inc. (NASDAQ:ALEC) by 27.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,334 shares of the company’s stock after purchasing an additional 8,581 shares during the period. SG Americas Securities LLC’s holdings in Alector were worth $74,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in Alector by 64.7% during the third quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock valued at $12,716,000 after purchasing an additional 1,072,298 shares during the last quarter. Creative Planning grew its holdings in Alector by 54.2% during the third quarter. Creative Planning now owns 19,117 shares of the company’s stock valued at $89,000 after purchasing an additional 6,723 shares during the last quarter. Barclays PLC grew its stake in shares of Alector by 132.4% in the third quarter. Barclays PLC now owns 176,800 shares of the company’s stock worth $824,000 after acquiring an additional 100,731 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Alector by 24.2% in the third quarter. Jane Street Group LLC now owns 154,942 shares of the company’s stock worth $722,000 after acquiring an additional 30,180 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Alector in the third quarter worth $90,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ALEC shares. Mizuho downgraded shares of Alector from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $9.00 to $2.50 in a research note on Tuesday, December 17th. Bank of America downgraded shares of Alector from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $9.00 to $1.00 in a research note on Wednesday, December 4th. Stifel Nicolaus downgraded shares of Alector from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Monday, December 16th. BTIG Research lowered their price target on shares of Alector from $16.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Finally, HC Wainwright lowered their price target on shares of Alector from $35.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.75.

Alector Stock Performance

Shares of NASDAQ:ALEC opened at $1.67 on Friday. Alector, Inc. has a 52 week low of $1.55 and a 52 week high of $7.58. The company’s fifty day moving average is $1.84 and its 200-day moving average is $3.80. The company has a market capitalization of $163.54 million, a PE ratio of -0.98 and a beta of 0.61.

Insider Activity

In other news, CFO Marc Grasso sold 16,489 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $41,552.28. Following the sale, the chief financial officer now owns 330,651 shares in the company, valued at approximately $833,240.52. The trade was a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Arnon Rosenthal sold 52,172 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total transaction of $131,473.44. Following the completion of the sale, the chief executive officer now owns 2,507,074 shares in the company, valued at $6,317,826.48. This represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 95,161 shares of company stock worth $239,806. Corporate insiders own 9.10% of the company’s stock.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.